Member Exclusive News

The week in industry: BenevolentAI secures $90 million investment to advance their drug development programs

This week: NHS England determines Vertex’s drug cost not justified, Multiple myeloma antibody treatment given FDA Orphan Drug Designation and Acceleron (MA, USA) discontinues development of muscular dystrophy drug.

Go to the profile of RxNet
Sep 19, 2019
0
0

Please sign in or register for FREE

No comments yet.